Table 4.
Medication Trials in Hepatitis B and Hepatitis C Coinfected Patients
| Author [Ref] | Patients | # | Treatment × Duration | HCV SVR | HBV DNA negative | HBsAg loss | HBeAg loss | SBR |
| Interferon Trials | ||||||||
| Gehenot [53] | Anti-HCV+ HCV RNA+ HBsAg+ HBV DNA- |
16 | IFNα 3 MU TIW × 6 mo | N/A | N/A | 12.5% | N/A | 19% |
| Weltman [3] | Anti-HCV+ HBsAg+ |
8 | IFNα 3 MU TIW × 6 mo | N/A | N/A | 12.5% | N/A | 12.5% |
| Guptan [54] | Anti-HCV+ HCV RNA+ HBsAg+ HBV DNA+ |
7 | IFNα 6 MU TIW × 6 mo | 29% | 86% | 28.6% | 100% | 0% |
| Villa [55] | Anti-HCV+ HCV RNA+ HBsAg+ |
30 | IFNα 9 MU TIW × 6 mo or 6 MU TIW × 6 mo | 16.7% (31%)* | 66.7% (100%)* | 3% | N/A | 20% (37.5%)* |
| Utili [23] | Anti-HCV+ HBeAg ± HCV RNA ± |
16 | IFNα 5 MU TIW × 12 mo | 43.8% | N/A | N/A | 15.4% | 50% |
| Zignego [10] | Anti-HCV+ HBV DNA+ HBsAg- |
14 | IFNα 3 MU TIW × 12 mo | 0% | 0% | N/A | N/A | 0% |
| Liaw [56] | Anti-HCV+ HBV DNA+ HBeAg+ |
15 | IFNα 9 MU TIW × 14 wk or 4–6 MU TIW × 12 wk | 0% | 6.7% | 6.7% | 6.7% | 6.7% |
| Interferon plus ribavirin trials | ||||||||
| Liu [57] | Anti-HCV+ HCV RNA+ HBsAg+ |
21 | IFNα 6 MU TIW × 3 mo + 3 MU TIW × 3 mo + ribavirin × 6 mo | 43% | 35% | 0% | 100% | 43% |
| Hung [58] | Anti-HCV+ HCV RNA+ HBsAg+ |
36 | IFNα 3–5 MU TIW + ribavirin × 6 mo | 69% | 11% | 0% | 0% | 56% |
| Chuang [59] | Anti-HCV+ HCV RNA+ HBsAg+ |
42 | IFNα 6 MU TIW + ribavirin × 6 mo | 69% | 31.3% | 14.3% | 50% | 54.8% |
| Interferon plus lamivudine trials | ||||||||
| Marrone [61] | HBeAg+ HBV DNA+ HCV RNA+ |
8 | IFN 5 MU TIW × 12 mo + lamivudine × 18 mo | 50% | 37.5% | 0% | 37.5% | 50% |
*9 MU arm. Abbreviations: # = number of patients; Ref = reference; SVR = sustained virologic response; SBR = sustained biochemical response; HCV = hepatitis C virus; HBV = hepatitis B virus; Anti-HCV = Antibody to hepatitis C virus; HBsAg = hepatitis B surface antigen; HBeAg = hepatitis B e antigen; mo = month; wk = week; TIW = thrice weekly; IFNα = interferon alfa